- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03277274
A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954
A Phase 1, Non-Randomized, Open-Label Trial to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being tested in this study is called TAK-954. This study will evaluate the safety and tolerability of single intravenous doses of TAK-954 in participants with varying degrees of hepatic function.
The study will enroll approximately up to 32 participants. Participants will be enrolled in one of the 4 treatment groups based on their degree of hepatic impairment which will be determined based on Child-Pugh Score as follow:
- Group 1 TAK-954 0.2 mg: Mild Hepatic Impairment (Child Pugh Class A)
- Group 2 TAK-954 0.2 mg: Moderate Hepatic Impairment (Child Pugh Class B)
- Group 3 TAK-954 0.2 mg: Severe Hepatic Impairment (Child Pugh Class C)
- Group 4 TAK-954 0.2 mg: Healthy Participants
The Child-Pugh classification will assess the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, prothrombin time, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
All participants will receive a single dose of TAK-954 0.2 mg on Day 1.
This study may have a full study design, where Group 1 to Group 4 will enroll approximately 8 participants in each group or a reduced study design, where no participants will be enrolled in Group 1 and approximately 8 participants will be enrolled in Group 2 to Group 4.
This multi-center trial will be conducted in Czech Republic and Slovakia. The overall time to participate in this study is approximately 7 weeks. Participants will remain confined to the clinic for 4 days, with 2 further out-patient visits, and will make a final visit to the clinic 10-14 days after receiving their last dose of TAK-954 for a follow-up assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female participants (non-childbearing potential), with a body mass index (BMI) between 18 to 35 kilogram per square meter (kg/m^2) (All participants).
- Participants with hepatic impairment who are medically stable as determined by the investigator, based on medical history and clinical evaluations including physical examinations, clinical laboratory tests, vital sign measurements, and 12-lead ECGs performed at the Screening Visit and at check-in on Day -1 (Group 1 to 3).
- Healthy participants (Group 4).
Exclusion Criteria:
Participants who have:
- A history of hepatic carcinoma, hepatorenal syndrome, or presence of a liver mass by ultrasound, CT or MRI, or acute liver disease caused by an infection or drug toxicity (Group 1 to 3).
- Have severe hepatic encephalopathy ([greater than] > Grade II Portal Systemic Encephalopathy Score) (Group 1 to 3).
- Surgical porto-systemic shunts, including transjugular intrahepatic portosystemic shunt (Group 1 to 3).
- A history of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 1 month prior to trial entry (Group 1 to 3).
- Bilirubin levels above 5 times the upper limit of normal (ULN) at screening or Day -1 for Groups 1 and 2, there is no limit for Group 3.
- Severe/advanced ascites and/or pleural effusion which requires emptying and albumin supplementation, as judged by the investigator (Group 1 to 3).
- Renal creatinine clearance (CLcr) less than or equal to (<=) 50 milliliter per minute (mL/min), calculated using the Cockcroft-Gault equation from the serum creatinine measurement taken at screening (Group 1 to 3).
- Who have a history of clinically significant endocrine, gastrointestinal (GI) (including motility disorder and intestinal obstruction), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial (Group 4).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg
TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
|
TAK-954 intravenous infusion.
|
Experimental: Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg
TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
|
TAK-954 intravenous infusion.
|
Experimental: Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg
TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
|
TAK-954 intravenous infusion.
|
Experimental: Group 4 Healthy Participants: TAK-954 0.2 mg
TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
|
TAK-954 intravenous infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)
Time Frame: Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
|
AUClast: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Total and Free)
Time Frame: Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
|
AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for TAK-954 (Total and Free)
Time Frame: Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Clinically Significant Physical Examination Findings
Time Frame: Up to 14 days after the last dose of study drug (Day 15)
|
Up to 14 days after the last dose of study drug (Day 15)
|
Number of Participants With Markedly Abnormal Electrocardiograms (ECGs)
Time Frame: Up to 14 days after the last dose of study drug (Day 15)
|
Up to 14 days after the last dose of study drug (Day 15)
|
Number of Participants With Markedly Abnormal Values of Vital Signs
Time Frame: Up to 14 days after the last dose of study drug (Day 15)
|
Up to 14 days after the last dose of study drug (Day 15)
|
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values
Time Frame: Up to 14 days after the last dose of study drug (Day 15)
|
Up to 14 days after the last dose of study drug (Day 15)
|
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
Time Frame: Baseline up to 30 days after last dose of study drug (Day 31)
|
Baseline up to 30 days after last dose of study drug (Day 31)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAK-954-1006
- 2017-000714-37 (EudraCT Number)
- U1111-1196-9190 (Registry Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on TAK-954
-
TakedaTakeda Development Center Americas, Inc.CompletedPostoperative Gastrointestinal DysfunctionUnited States, Germany
-
Millennium Pharmaceuticals, Inc.Completed
-
TakedaCompletedRenal Impairment | Healthy VolunteersCzechia, Hungary
-
Millennium Pharmaceuticals, Inc.Completed
-
TakedaCompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
AbbVieInfinity Pharmaceuticals, Inc.Completed
-
Millennium Pharmaceuticals, Inc.TerminatedCritical Illness | Enteral Nutrition | Enteral Feeding IntoleranceUnited States, Canada, Australia, United Kingdom